Non-small cell lung cancer (NSCLC) is an aggressive malignancy that remains the leading cause of cancer-related deaths, even though survival has improved since the introduction of immunotherapy and targeted treatments [1–3]. The first-line (1 L) treatment standard for advanced NSCLC is...
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib’s potential as a...
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib's potential as a...
Bruna Pellini: Our New Manuscript Explores Sotorasib Plus T-DXd in KRAS G12C-Mutant NSCLC / Andriy Marusyk, Bina Desai, Bruna Pellini, cancer, Denise Kalos, Bruna Pellini/LinkedIn Bruna Pellini: Our New Manuscript Explores Sotorasib Plus T-DXd in KRAS G12C-Mutant NSCLC Bruna Pellini,...
T-DXd Plus Sotorasib in KRAS G12C-Mutant NSCLC showed durable preclinical tumor regressions and highlighted HER2 testing gaps T-DXd Plus Sotorasib Shows Preclinical Promise in KRAS G12C-Mutant NSCLC KRAS G12C-mutant non-small cell lung cancer has become one of the clearest examples...
Zoldonrasib (RMC-9805), a novel KRAS G12D RAS(ON) inhibitor, has demonstrated “promising activity” while being “very well tolerated” among patients with KRAS G12D-mutated non–small cell lung cancer (NSCLC), according to Jonathan Wesley Riess, MD, MS. In a conversation with CancerNetwork®, Riess...
Zoldonrasib (RMC-9805), an investigational RAS(ON) inhibitor, exhibited promising antitumor activity among patients with previously treated KRAS G12D-mutated non–small cell lung cancer (NSCLC), according to a presentation on findings from the phase 1/1b RMC-9805-001 study (NCT06040541) at the 2026 American Association...
Generation kras g12c inhibitor elisrasib: Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with locally advanced or metastatic non-small Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with...
